卡介苗初次免疫-增强免疫策略抗结核病的研究进展

摘要/Abstract

摘要： 据WHO统计，全球TB的发病率和新发患者数在近几年来均呈现下降趋势。2010年全球报告病例约880万，145万例死亡，这受益于各国对TB防治的重视和新技术在TB防治上的应用。但要实现TB的有效控制和WHO提出的2050年消除TB对全球公共卫生的影响的目标，仍面临着几个重大的问题：全球约1/3的人口感染了Mtb成为潜伏感染者（latent TB infection, LTBI），且5%～10%的LTBI一生中可能经内源性感染发展成为活动性TB患者；耐多药结核病（MDR-TB）在TB高负担国家流行，广泛耐药结核病（XDR-TB）甚至完全耐药结核病（TDR-TB）等已经出现；与HIV共感染，TB患者的病死率增加。这些都对TB的防治提出了更高的要求。

陈振华范雄林. 卡介苗初次免疫-增强免疫策略抗结核病的研究进展[J]. 中国防痨杂志, 2012, 34(3): 188-191.

. Research progress in BCG prime-boost vaccination strategy against tuberculosis[J]. Chinese Journal of Antituberculosis, 2012, 34(3): 188-191.

参考文献

［1］WHO Library Cataloguing-in-Publication Data. Global tuberculosis control 2011［EB/OL］［2011-11-28］. http://www.who.int/tb/publications/global_report/en/.

［2］Zignol M，Hosseini MS，Wright A，et al.Global incidence of multidrug-resistant tuberculosis. J Infect Dis,2006,194(4)：479-485.

［3］Shah NS，Wright A，Bai GH，et al.Worldwide emergence of extensively drug-resistant tuberculosis.Emerg Infect Dis，2007，13(3)：380-387.

［4］Centers for Disease Control and Prevention (CDC).Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs——worldwide，2000—2004.MMWR Morb Mortal Wkly Rep，2006，55 (11)：301-305.

［5］Dheda K，Migliori GB.The global rise of extensively drug-resistant tuberculosis：is the time to bring back sanatoria now overdue? Lancet，2011，Oct 25.［Epub ahead of print］.

［6］Fennelly KP.Variability of airborne transmission of Mycobacterium tuberculosis：implications for control of tuberculosis in the HIV era.Clin Infect Dis,2007,44 (10)：1358-1360.

［7］World Health Organization.BCG vaccine.WHO position paper［Article in English，French］.Wkly Epidemiol Rec，2004,79(4):27-38.

［8］Fine PE.Variation in protection by BCG：implications of and for heterologous immunity.Lancet，1995，346 (8986)：1339-1345.

［9］Colditz JA，Brewer TF，Berkey CS，et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.JAMA，1994，271 (9)：698-702.

［10］Tullius MV，Harth G，Maslesa-Galic S，et al. A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.Infect Immun,2008,76 (11):5200-5214.

［11］Grode L，Seiler P，Baumann S，et al.Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.J Clin Invest，2005，115(9)：2472-2479.

［12］Sun R，Skeiky YA，Izzo A，et al.Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization，safety and protection against challenge with Mycobacterium tuberculosis.Vaccine，2009，27 (33):4412-4423.

［13］Wang J，Qie Y，Zhu B，et al.Evaluation of a recombinant BCG expressing antigen Ag85B and PPE protein Rv3425 from DNA segment RD11 of Mycobacterium tuberculosis in C57BL/6 mice.Med Microbiol Immunol，2009，198 (1):5-11.

［14］Shi C，Chen L，Chen Z，et al.Enhanced protection against tuberculosis by vaccination with recombinant BCG overexpressing HspX protein.Vaccine,2010,32(28):5237-5244.

［15］Sambandamurthy VK，Derrick SC，Hsu T,et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD：a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.Vaccine，2006，24 (37-39)：6309-6320.

［16］Asensio JA, Arbués A, Pérez E,et al.Live tuberculosis vaccines based on phoP mutants：a step towards clinical trials.Expert Opin Biol Ther，2008，8 (2):201-211.

［17］Corner LA，Buddle BM，Pfeiffer DU，et al. Vaccination of the brushtail possum (Trichosurus vulpecula) against Mycobacterium bovis infection with bacille Calmette-Guérin: the response to multiple doses.Vet Microbiol，2002，84 (4)：327-336.

［18］Feng CG，Palendira U，Demangel C，et al.Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacilli Calmette-Guérin against tuberculosis.Infect Immun，2001，69 (6)：4174-4176.

［19］Santosuosso M，McCormick S，Zhang X，et al.Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parental Mycobacerium bovis BCG immunization against pulmonary tuberculosis.Infect Immun，2006，74 (8)：4634-4643.

［20］Goonetilleke NP，McShane H，Hannan CM，et al.Enhanced immunogenecity and protective efficacy against Mycobacterium tuberculosis of bacilli Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.J Immunol，2003，171 (3)：1602-1609.

［21］Buddle BM，Wedlock DN，Parlane NA，et al. Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination.Infect Immun，2003，71 (11)：6411-6419.

［22］Tala-Heikkila MM, Tuominen JE, Tala EO.Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence.Am J Respir Crit Care Med，1998，157 (4 Pt 1)：1324-1327.

［23］WHO. Immunization，vaccines and biologicals［EB/OL］.［2011-11-29］.http://www.who.int/immunization/en/.

［24］Trnka L，Dankova D，Zitova J，et al.Survey of BCG vaccination policy in Europe：1994—96. Bull World Health Organ，1998，76 (1)：85-91.

［25］Barreto ML，Pereira SM，Pilger D，et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC clusterrandomised trial. Vaccine，2011，29 (31)：4875-4877.

［26］Karonga Prevention Trial Group.Randomised controlled trial of single BCG，repeated BCG，or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi.Lancet，1996，348 (9019)：17-24.

［27］Expanded programme on immunization. Immunization schedules in the WHO European Region, 1995. Wkly Epidem Rec，1995，70 (31)：221.

［28］中华人民共和国卫生部.关于停止卡介苗复种的通知（卫疾控发［1997］第26号）.北京，1997：1-2.

［29］Rouanet C，Locht C.Boosting BCG to protect against TB.Expert Rev Respir Med，2010，4 (3)：339-348.

［30］Fletcher HA，Hawkridge T，McShane H. A New Vaccine for Tuberculosis: The Challenges of Development and Deployment. J Bioeth Inq，2009，6(2)：219-228.

［31］Kaufmann SH.How can immunology contribute to control of tuberculosis? Nat Rev Immunol，2001,1(1):20-30.

［32］Brandt L，Skeiky YA，Alderson MR，et al.The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72kilodalton fusion polyprotein Mtb72F in M.tuberculosis infected guinea pigs.Infect Immun,2004，11 (72):6622-6632.

［33］Andersen CS，Dietrich J，Agger EM，et al.The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun，2007，75 (1):408-416.

［34］Dietrich J，Andersen C，Rappuoli R，et al.Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guérin immunity.J Immunol，2006，177(9):6353-6360.

［35］Brooks JV，Frank AA，Keen MA，et al.Boosting vaccine for tuberculosis.Infect Immun，2001,69 (4):2714-2717.

［36］Majlessi L，Simsova M，Jarvis Z，et al.An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.Infect Immun，2006，74 (4)：2128-2137.

［37］Horwitz MA，Harth G，Dillon BJ，et al.Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.Infect Immun,2005,73 (8):4676-4683.

［38］Rouanet C，Debrie AS，Lecher S，et al.Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis.Microbes Infect,2009,13 (11):995-1001.

［39］范雄林，李元，徐志凯.结核分枝杆菌基因疫苗研究进展.细胞与分子免疫学杂志，2001,17增刊:121-123.

［40］Fan X，Gao Q，Fu R.Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model.Microbiol Res,2009,16(4):374-382.

［41］Mollenkopf HJ，Grode L，Mattow J，et al.Application of mycobacterial proteomics to vaccine design：improved protection to Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis.Infect Immun,2004,72(11):6471-6479.

［42］Fan X，Gao Q，Fu R.DNA vaccine encoding ESAT-6 enhances the protective efficacy of BCG against Mycobacterium tuberculosis infection in mice.Scand J Immun,2007，66(5):523-528.

［43］Derrick SC，Yang AL，Morris SL.A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacerium tuberculosis and boosts BCG induced protective immunity.Vaccine，2004，23(6)，780-788.

［44］Badell E，Nicolle F，Clark S,et al.Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85BESAT-6 does not correlate with circulating IFN-gamma producing T-cells.Vaccine，2009，27(1):28-37.

［45］Wang C，Chen Z，Fu R，et al.A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice.Med Microbiol Immun，2011，200(3):165-175.

［46］Lu J，Wang C，Zhou Z，et al.Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.Clin Dev Immunol,2011，2011:617892.

［47］Maue AC, Waters WR, Palmer MV,et al.An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis.Vaccine，2007，25(24)：4735-4746.

［48］Okada M，Kita Y，Nakajima T，et a1.Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA+IL-12 DNA) against tuberculosis using the cynomolgus monkey model of TB.Vaccine，2007，25(16)：2990-2993.

［49］Williams A，Hatch GJ，Clark SO，et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb)，2005，85(1/2)：29-38.

［50］Verreck FA，Vervenne RA，Kondova I，et al.MVA85A boosting of BCG and an attenuated, phoP deficient M.tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.PLoS One，2009，4(4)：e5264.

［51］Pathan AA，Sander CR，Fletcher HA，et al.Boosting BCG with recombinant modified vaccinia Ankara expressing antigen 85A：different boosting intervals and implications for efficacy trials.PLoS One，2007，2 (10)：e1052.

［52］Hawkridge T，Scribz TJ，Gelderbloem S，et al.Safety and immunogenicity of a new tuberculosis vaccine，MVA85A，in healthy adults in South Africa.J Infect Dis，2008，198(4)：544-552.

［53］Scriba TJ，Tameris M，Mansoor N，et al.Dose-finding study of the novel tuberculosis vaccine，MVA85A，in healthy BCG-vaccinated infants. J Infect Dis，2011，203 (12):1832-1843.

［54］Sander CR, Pathan AA, Beveridge NE，et al.Safety and immunogenicity of a new tuberculosis vaccine，MVA85A，in Mycobacterium tuberculosis infected individuals.Am J Respir Crit Care Med，2009，179(8)：724-733.

［55］Wang J，Thorson L，Stokes RW，et al.Single mucosal，but not parenteral，immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.J Immunol，2004，173(10)：6357-6365.

［56］Xing Z，Santosuosso M，McCormick S，et al.Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccine.Curr Gene Ther，2005，5(5)：485-492.

［57］Xing Z，McFarland CT，Sallenave JM，et al. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.PLoS One，2009，4 (6)：e5856.

［58］Santosuosso M，McCormick S，Zhang X，et al.Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.Infect Immun,2006,74(8):4634-4643.

［59］Abel B，Tameris M，Mansoor N，et al.The novel tuberculosis vaccine，AERAS-402，induces robust and polyfunctional CD4⁺ and CD8⁺T cells in adults.Am J Respir Crit Care Med，2010，181(12)：1407-1417.